OTTAWA, June 14, 2002 - Industry Minister Allan Rock today announced the appointment of Dr. Alan Bernstein to the Board of Directors of the Canada Foundation for Innovation (CFI). Dr. Bernstein who is President of the Canadian Institutes of Health Research (CIHR) was appointed for a two-year term.
"Dr. Bernstein's appointment is part of our vision to mobilize Canada's most prominent citizens and institutions to help place our country among the world's most innovative nations," said Minister Rock. "It is also part of our commitment to Canadians to ensure the transparency and excellence of publicly-funded organizations."
Dr. Bernstein brings to the CFI research achievement and leadership in the health sector that will help the Foundation keep its strong focus on the partnership approach that is at the core of its mandate.
The CFI is an independent, not-for-profit corporation established by the Government of Canada in 1997 to support the development of world-class research infrastructure at Canadian universities, colleges, hospitals and research institutions. The CFI Board of Directors is comprised of 15 prominent Canadians representing academia, industry, government and the voluntary sector. The Board of Director is responsible for funding decisions and is accountable to 15 Members who act as the Foundation's shareholders on behalf of the Government of Canada.
The CFI has been entrusted with a capital investment budget of $3.15 billion.
For information, please contact:
Canada Foundation for Innovation
douglas.lauriault [at] innovation.ca
Alan Bernstein, PhD, FRSC
Canadian Institutes of Health Research
Dr. Alan Bernstein is known internationally both as a researcher and as a scientific leader. His pioneering research in the area of cancer, hematopoiesis and gene therapy remain landmarks in their field.
Dr. Bernstein received his Ph.D. in Medical Biophysics at the University of Toronto in 1972. Following postdoctoral work at the Imperial Cancer Research Fund Laboratories in London (UK), he joined the Ontario Cancer Institute and the University of Toronto in 1974. He has been a Professor of Molecular and Medical Genetics since 1984. In 1985, Dr. Bernstein moved to Mount Sinai Hospital as Head of Molecular and Developmental Biology of its Samuel Lunenfeld Research Institute. Three years later he became Associate Director and Director in 1994, a position he held until June , 2000 when he was appointed the inaugural President of the Canadian Institutes of Health Research.
A productive scientist, Dr. Bernstein is the author or co-author of almost 200 refereed articles. He has made key contributions to our understanding of embryonic development, hematopoiesis, cancer and formation of the cardiovascular system. His work has also been important in advancing techniques for gene therapy and the genetic analysis of mammalian development.
As a scientific leader, Dr. Bernstein was highly successful in building and nurturing the Lunenfeld Institute into one of Canada's premier health research institutes.
Dr. Bernstein held the first Anne Tanenbaum Chair in Molecular and Developmental Biology at the Lunenfeld from 1990-2000, The Koffler Chair for the Director of the Lunenfeld (1994-2000). He has also received numerous awards and honours for his work, including the Genetics Society of Canada Award of Excellence, the Robert L. Noble Award from the National Cancer Institute of Canada, the Royal Society of Canada's McLaughlin Medal, and the 2001 Medal from the Australian Society for Medical Research.